The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China ...

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Illumina shareholders received a warning shot. In response to President Trump’s initial tariff measures, the Chinese ...

Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...

La empresa local de secuenciación genética citó ahorros de costos para alinearse con su futura estrategia comercial.

Canaccord lowered the firm’s price target on Illumina (ILMN) to $115 from $135 and keeps a Hold rating on the shares. The firm’s target ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth ...

China banned the import of Illumina Inc. gene-sequencing machines as part of a wave of retaliatory trade measures in response ...